We examined the degree of association between two neurologic impairment scales, the Extended Disability Status Scale (EDSS) and the Scripps Neurologic Rating Scale (SNRS), with data from a randomized, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of cladribine as treatment for chronic progressive multiple sclerosis (MS). We found that the EDSS and SNRS were not strongly correlated within individual patients, contrary to expectation; moreover, in 9 of the 48 evaluable patients, the directions of their changes from baseline values were not mutually consistent. The scales were differentially sensitive to clinical changes over time, with the EDSS indicating a more abrupt, and the SNRS a more gradual, change in the clinical course of disease. The validity of different impairment scales, and their sensitivity to detect clinical changes, should be formally assessed in future clinical trials using these scales as outcome measures.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Willoughby EW, Paty DW (1988) Scales for rating impairment in multiple sclerosis: a critique. Neurology 38:1793–1798
Mumford CJ, Compston A (1993) Problems with rating scales for multiple sclerosis: a novel approach — the CAMBs score. J Neurol 240:209–215
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
Noseworthy JH, Vandervoort MK, Hopkins M, Ebers GC (1989) A referendum on clinical research in multiple sclerosis: the opinion of the participants in the Jekyll Island workshop. Neurology 39:977–981
Ellison GW, Myers LW, Leake BD, Mickey MR, Ke D, Syndulko K, Tourtellotte WW (1994) Design strategies in multiple sclerosis clinical trials. Ann Neurol 36:S108-S112
Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344:9–13
Sipe JC, Knobler RL, Braheny SL, Rice GPA, Panitch HS, Oldstone MBA (1984) A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 34:1368–1372
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellote WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
Kurtzke JF (1986) Neuroepidemiology. II. Assessment of therapeutic trials. Ann Neurol 19:311–319
Kendall MG, Gibbons JD (1990) Rank correlation methods, 5th edn. Oxford University Press, New York
Muir KW, Grosset DG, Lees KR (1994) Interconversion of stroke scales. Implications for therapeutic trials. Stroke 25:1366–1370
Cleveland WS (1979) Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829–836
Koziol JA, Hacke W (1990) Multivariate data reduction by principal components with application to neurological scoring instruments. J Neurol 237:461–464
Deyo RA, Centor RM (1986) Assessing the responsiveness of functional scales to clinical change: an analogy to diagnostic test performance. J Chronic Dis 39:897–906
Nunally JC (1978) Psychometric theory. McGraw Hill, New York
Carmines EG, Zeller RA (1979) Reliability and validity assessment. Sage Publications, Beverly Hills, Calif
Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12:142S-158S
About this article
Cite this article
Koziol, J.A., Frutos, A., Sipe, J.C. et al. A comparison of two neurologic scoring instruments for multiple sclerosis. J Neurol 243, 209–213 (1996). https://doi.org/10.1007/BF00868516
- Extended Disability
- Status Scale Scripps
- Neurologic Rating Scale
- Multiple sclerosis